| Document |
Document Title |
|
WO/2024/060460A1 |
Provided are a stem cell-derived gastruloid model, a method for constructing same, and use. The gastruloid model is acquired by means of in vitro construction from a human pluripotent stem cell. The model can simulate biological events o...
|
|
WO/2024/060205A1 |
Disclosed are a nucleic acid molecule comprising an alternative splicing regulatory element and a target gene located at the 3' terminus of the alternative splicing regulatory element, a transcript of the nucleic acid molecule, a vector ...
|
|
WO/2024/064952A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the sternness of the immune cells. In some aspects, the immune cells which are c...
|
|
WO/2024/060422A1 |
Disclosed are a double-targeting CAR-T cell targeting mesothelin and an NKG2D ligand and use thereof, and particularly disclosed is a chimeric antigen receptor, which comprises a nanobody targeting mesothelin and a protein targeting an N...
|
|
WO/2024/061984A1 |
The invention relates to methods of forward programming an induced pluripotent stem cell (iPSC) into a somatic cell, said methods comprising at least dual targeting of safe harbour sites in the genome of an iPSC. The invention also inclu...
|
|
WO/2024/063533A1 |
The present invention relates to a high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells. The high-performance mature human intestinal organoid regenerative therapeutic agent...
|
|
WO/2024/059901A1 |
The invention is directed to compositions and methods for preventing or rescuing exhaustion of immune effector cells, especially CAR T cells. The compositions and methods comprise bispecific polypeptides with a first antigen binding prot...
|
|
WO/2024/060485A1 |
Provided herein are a method for preparing a hematopoietic stem cell or a hematopoietic stem and progenitor cell, and a method for culturing a long-term hematopoietic stem cell. The method for preparing a hematopoietic stem cell or a hem...
|
|
WO/2024/063999A1 |
Disclosed herein are methods of generating intestinal organoids (IO) with immune cells (iIO) and methods of making an iIO with activated immune cells. IO compositions including immune cells, optionally including activated immune cells, (...
|
|
WO/2024/063110A1 |
The present invention addresses the problem of providing an evaluation method of a test substance using an M cell model similar to M cells in a living human body. Provided is an evaluation method of a test substance, the method including...
|
|
WO/2024/059942A1 |
It is provided a cell macroencapsulation device for implanting cells in a recipient comprising cells encapsulated in a porous membrane, wherein the porous membrane consists of a sugar network coated with a polymeric solution comprising p...
|
|
WO/2024/064824A2 |
Genetically modified NK cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders. In some forms, the genetically modified NK cells have reduced or abrogated expression of the Cal...
|
|
WO/2024/061306A1 |
The present application discloses antibodies and antibody derivatives that bind to B7H3 (also known as CD276) and methods of using the same. The antibodies or antibody derivatives comprise a single domain antibody that binds to B7H3.
|
|
WO/2024/063020A1 |
Provided is an intervertebral disc therapeutic agent having favorable post-transplant engraftment. This intervertebral disc therapeutic agent contains scaffold-free artificial tissue in which synovium-derived mesenchymal stem cells form ...
|
|
WO/2024/064261A1 |
Embodiments of the present disclosure pertain to modified cells that include a fusion protein of NPC intracellular cholesterol transporter 2 protein (NPC2) and another protein. Additional embodiments of the present disclosure pertain to ...
|
|
WO/2024/061354A1 |
The present invention provides an interfering RNA targeting TOP1 gene. The interfering RNA can reduce the expression of TOP1, thereby treating a disease related to TOP1 expression. The present invention further provides a lipid nanoparti...
|
|
WO/2024/064160A1 |
Microphysiological platforms are configured for measuring kinetic rates relating to drug absorption. These kinetic rates include GI region-specific kinetic rates of drug absorption. The kinetic rates include bioavailability of the drug o...
|
|
WO/2024/060140A1 |
The present invention relates to a novel chimeric antigen receptor specifically binding to EGFRvIII and use thereof.
|
|
WO/2024/061759A1 |
The present invention relates to stabilized HCoV-NL63 S proteins, or fragments thereof, nucleic acid sequences encoding such proteins, as well as to uses thereof.
|
|
WO/2024/056738A1 |
The present invention relates to an allogeneic myeloid cell, such as a macrophage, for use in therapy, such as the treatment of cancer in a human patient, wherein the allogeneic myeloid cell, such as the allogeneic macrophage, comprises ...
|
|
WO/2024/058589A1 |
The present invention relates to a chimeric antigen receptor (CAR) cell prepared using genetic scissor knock-in, and a use thereof, and more specifically to a method for preparing a single guide RNA (sgRNA) for TGF beta receptor 2 (TGFBR...
|
|
WO/2024/059787A1 |
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and...
|
|
WO/2024/058155A1 |
The present invention addresses the problem of providing a new method for simply and efficiently producing linear covalently closed DNA. Provided is a double stranded circular DNA vector, wherein the double stranded circular DNA vector...
|
|
WO/2024/059776A2 |
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells ...
|
|
WO/2024/058511A1 |
The present invention relates to a method for differentiating stem cells into hard tissue, and uses different cell culture supports during differentiation so that differentiation into hard tissue can be induced through different cell dev...
|
|
WO/2024/055077A1 |
The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moi...
|
|
WO/2024/058198A1 |
Provided is a production method which is for induced pluripotent stem cells and by which induced pluripotent stem cells having high undifferentiation properties and differentiation potency are easily obtained. A production method for i...
|
|
WO/2024/057892A1 |
The present invention addresses the problem of providing a means for maintaining and enhancing the anti-tumor activity of TADC in a tumor microenvironment. It was found that when a composition, "cPLs adjuvant," containing three types o...
|
|
WO/2024/059208A2 |
The invention disclosed herein generally relates to methods and systems for growing, expanding and/or obtaining human intestinal organoids (HIOs) having a serosal mesothelial layer. In particular, the invention disclosed herein relates t...
|
|
WO/2023/133357A9 |
A therapeutic molecule (single chain-based antibody or ligand-based) optimized for expression and secretion from engineered T cells, which may be gamma delta (gd) T cells. When expressed from engineered gdT cells, the STAR will be secret...
|
|
WO/2024/059336A1 |
Provided are methods and compositions for treating or preventing lymphedema by administering an inhibitor of the protease-activated receptor 2 (PAR2) pathway.
|
|
WO/2024/055534A1 |
The present application relates to pharmaceutical use of Radix Dipsaci-derived extracellular vesicle-like nanoparticles, and in particular to use of Radix Dipsaci-derived extracellular vesicle-like nanoparticles in the preparation of a d...
|
|
WO/2024/059264A1 |
Described herein are compositions and methods for producing immune cells, such as regulatory T cells (Tregs), expressing a chimeric antigen receptor (CAR) which responds to a non-degradable engineered polymeric antigen in a site-specific...
|
|
WO/2024/058111A1 |
The present invention provides a method or the like for efficiently screening candidate substances for a hexanal-odor suppressing material. A screening method according to the present invention comprises: adding a test substance and hexa...
|
|
WO/2024/055893A1 |
A preparation method for a bionic multi-component fiber carrying seed cells, and an application thereof. The preparation method comprises the following steps: S1, 1) drawing and assembling tubes I with pointed ends; 2) drawing a tube II ...
|
|
WO/2024/058710A1 |
Disclosed herein are a method of identifying therapeutically potent mesenchymal stem cells (MSCs) and a method of distinguishing MSCs from human fibroblasts, comprising detecting HOXA9 expression in the cell. Also disclosed is a method o...
|
|
WO/2024/059170A1 |
Presented herein are methods, systems, and apparatus for performing one or more steps of a gene therapy using an infusion device, e.g., a rapid infusion device, e.g., for the treatment of a disease or condition. For example, it is presen...
|
|
WO/2024/059464A1 |
The invention provides recombinant DNA polynucleotides and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and s...
|
|
WO/2024/058234A1 |
The present invention provides human T cells lacking human leukocyte antigen (HLA) class I molecules and containing an exogenous ST6GALNAC6 gene, the T cells having the following characteristics (a) and/or (b): (a) being CD62L-positive a...
|
|
WO/2024/059740A1 |
Provided herein are polynucleotides and genetically modified cells comprising polynucleotides encoding a genetically modified major histocompatibility complex (MHC) associated polypeptide linked to an adapter peptide that is capable of b...
|
|
WO/2024/056560A1 |
The present invention relates to a recombinant expression vector encoding an inducible cell death switch, a pH-stable fluorophore and a pH-sensitive fluorophore. Moreover, the invention relates to cells comprising said recombinant expres...
|
|
WO/2024/059812A2 |
Tissue modulating systems, devices, and methods modulate and/or stimulate numerous tissue specimens, independently and in parallel, within a multi-well plate in such a way to allow simultaneous measurement of functional properties of the...
|
|
WO/2024/055995A1 |
Provided are an anti-VEGFA fusion protein, and a preparation method therefor and the use thereof. The anti-VEGFA fusion protein has a high affinity with VEGFA, can effectively block the binding of VEGFA to receptor VEGFR, block a VEGFA s...
|
|
WO/2024/055339A1 |
Provided are a genetically engineered feeder cell expressing CD19 and at least one molecule that stimulates immune cell activation, a method for preparing the genetically engineered feeder cell, and use of the genetically engineered feed...
|
|
WO/2024/059252A2 |
An ECM-embedded vascular channel-on-a-chip includes an outer case having an internal chamber, an ECM provided within the chamber, the ECM having a cross-sectionally rounded vascular channel having a first end and a second end opposite th...
|
|
WO/2024/056098A1 |
Provided are an NK cell adapter molecule targeting an NKG2D ligand and an NKp46 and the use thereof. The cell adapter molecule at least comprises: a first binding domain comprising an NKG2D extracellular domain that can specifically bind...
|
|
WO/2024/059584A1 |
In various aspects, the invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention further provides pluripotent stem cell-derived hematop...
|
|
WO/2024/059712A1 |
Disclosed herein are non-viral methods to ablate Activating transcription factor 6 (ATF6), X-box binding protein 1 (XBP1), and/or protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) in T cells while effectively expressing chi...
|
|
WO/2024/058679A1 |
The first object of the invention is a fibrin patch containing corneal limbal epithelial cells, characterized in that it contains a protein substrate, which is dried and rehydrated fibrin, a density of corneal limbal epithelial cells on ...
|
|
WO/2024/056601A1 |
The invention relates to devices for measuring cellular avidity and to processes for making and using the devices.
|
